Skip to content

Study · Non-randomized trial · n = 91 · 2005

13 results

Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.

Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research27 Apr 2005Cited by 96 (Europe PMC)

PMID16059627 (opens in a new tab)PMCIDPMC4445726 (opens in a new tab)DOI10.1359/jbmr.050411 (opens in a new tab)PepBankPUB-16059627
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, calcitonin preserved or improved distal radius apparent BV/TV compared with placebo deterioration (p < 0.03).

    In plain wordsIn women with osteoporosis, calcitonin preserved or improved wrist bone volume compared with deterioration with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseDistal radius apparent BV/TV
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    MRI assessment of trabecular microarchitecture at individual regions of the distal radius revealed significant improvement, or preservation (no significant loss), in the CT-NS-treated group compared with significant deterioration in the placebo control group, as reflected in apparent BV/TV (p < 0.03…
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, calcitonin preserved or improved distal radius trabecular number compared with placebo deterioration (p < 0.01).

    In plain wordsIn women with osteoporosis, calcitonin preserved or improved wrist trabecular number compared with deterioration with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseDistal radius apparent trabecular number
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    MRI assessment of trabecular microarchitecture at individual regions of the distal radius revealed significant improvement, or preservation (no significant loss), in the CT-NS-treated group compared with significant deterioration in the placebo control group, as reflected in apparent BV/TV (p < 0.03…
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, calcitonin preserved or improved distal radius trabecular spacing compared with placebo deterioration (p < 0.01).

    In plain wordsIn women with osteoporosis, calcitonin preserved or improved wrist trabecular spacing compared with deterioration with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseDistal radius apparent trabecular spacing
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    MRI assessment of trabecular microarchitecture at individual regions of the distal radius revealed significant improvement, or preservation (no significant loss), in the CT-NS-treated group compared with significant deterioration in the placebo control group, as reflected in apparent BV/TV (p < 0.03…
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  4. 04HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, calcitonin preserved lower trochanter trabecular microarchitecture compared with placebo (p < 0.05).

    In plain wordsIn women with osteoporosis, calcitonin preserved bone structure at the lower trochanter compared with placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseLower trochanter microarchitecture
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Also, at the hip, the CT-NS group exhibited preservation of trabecular microarchitecture at the lower trochanter (p < 0.05) as determined by T2* MRI technology.
    2 context sentences
    Summary · context
    In the distal radius and lower trochanter of the hip, individuals treated with CT-NS exhibited significant preservation of trabecular bone microarchitecture compared with placebo, where significant deterioration was shown.
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  5. 05HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, other os calcis architecture measures showed no significant changes within or between groups.

    In plain wordsIn women with osteoporosis, other heel bone structure measures showed no significant changes within or between groups.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeOther os calcis architecture measures
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Apart from a significant increase in apparent trabecular number in the CT-NS group, significant changes within or between groups were not noted at the os calcis.
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  6. 06HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, iliac crest microCT/histomorphometry did not differ significantly between calcitonin and placebo.

    In plain wordsIn women with osteoporosis, pelvic bone biopsy structure did not differ significantly between calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeIliac crest microCT/histomorphometry
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Combined microCT/histomorphometric analysis of iliac crest bone biopsies did not reveal significant differences between treated and placebo groups.
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  7. 07HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, calcitonin preserved microarchitecture regardless of BMD change, while placebo showed loss or preservation.

    In plain wordsIn women with osteoporosis, calcitonin preserved bone structure despite bone density gains or losses, while placebo showed loss or preservation.

    Peptide
    Calcitonin-salmon
    Outcome
    MixedMicroarchitecture independent of BMD change
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    In the CT-NS group, regardless of the change in BMD (gain or loss) at the spine, hip, or distal radius, preservation of parameters of trabecular microarchitecture was noted, whereas in the placebo group, regardless of the change in BMD (gain or loss) at the spine, hip, or distal radius, loss or preservation was noted;
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  8. 08HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, spine DXA/BMD changes did not differ significantly between calcitonin and placebo.

    In plain wordsIn women with osteoporosis, spine bone density changes did not differ significantly between calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeSpine DXA/BMD
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    however, changes in DXA/BMD (of the spine, hip, wrist, os calcis) between CT-NS and placebo groups were not significant.
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  9. 09HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, hip DXA/BMD changes did not differ significantly between calcitonin and placebo.

    In plain wordsIn women with osteoporosis, hip bone density changes did not differ significantly between calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeHip DXA/BMD
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    however, changes in DXA/BMD (of the spine, hip, wrist, os calcis) between CT-NS and placebo groups were not significant.
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  10. 10HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, wrist DXA/BMD changes did not differ significantly between calcitonin and placebo.

    In plain wordsIn women with osteoporosis, wrist bone density changes did not differ significantly between calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeWrist DXA/BMD
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    however, changes in DXA/BMD (of the spine, hip, wrist, os calcis) between CT-NS and placebo groups were not significant.
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  11. 11HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, os calcis DXA/BMD changes did not differ significantly between calcitonin and placebo.

    In plain wordsIn women with osteoporosis, heel bone density changes did not differ significantly between calcitonin and placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeOs calcis DXA/BMD
    Study

    n = 91

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    however, changes in DXA/BMD (of the spine, hip, wrist, os calcis) between CT-NS and placebo groups were not significant.
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  12. 12HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, apparent trabecular number increased significantly at the os calcis with calcitonin.

    In plain wordsIn women with osteoporosis, heel trabecular number increased significantly from baseline during calcitonin treatment.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseOs calcis apparent trabecular number
    Study

    n = 46

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Apart from a significant increase in apparent trabecular number in the CT-NS group, significant changes within or between groups were not noted at the os calcis.
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.
  13. 13HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporotic women, serum C-telopeptide decreased by 22.5% at 24 months (p = 0.056) with calcitonin.

    In plain wordsIn women with osteoporosis, the bone resorption marker decreased by 22.5% at 24 months (p = 0.056) with calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSerum C-telopeptide
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 yearsAs given in this study (human).

    Measurements

    Serum C-telopeptide reduction
    22.5%
    calcitonin nasal spray at 24 months (p = 0.056)

    Source sentences

    Summary
    Serum C-telopeptide (S-CTx), a specific bone resorption marker, was reduced by 22.5% at 24 months (p = 0.056).
    1 context sentence
    Summary · context
    Ninety-one postmenopausal osteoporotic women were followed for 2 years (n = 46 for CT-NS, n = 45 for placebo); all women received 500 mg calcium daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.